Literature DB >> 1742942

HLA antigen frequencies in children born to HIV-infected mothers.

D C Kilpatrick1, R A Hague, P L Yap, J Y Mok.   

Abstract

Tissue-typing for HLA-A, B, and DR antigens was carried out on 53 babies, 47 of them unrelated, born to mothers known to be HIV-infected from intravenous drug usage or sexual contact with drug users. These babies were followed up to assess whether HLA phenotype was associated with vertical transmission of HIV infection or disease progression. Of the 47 unrelated babies, eight became infected with HIV. The frequency of HLA-DR3 was three times higher in the HIV-positive infants compared to the HIV-negative infants (43 per cent vs 15 per cent) in our study population. Conversely, HLA-A3 was three times less common in the HIV-positive infants (12.5 per cent vs 42 per cent). A comparison of HLA antigens between our study group babies and babies born to healthy mothers unselected for HIV status revealed higher proportions of HLA-B18, B7, and DR2 in the study group. Moreover, the combination, A3, B7, DR2 was four times commoner in our study population relative to controls (RR = 3.9; p less than 0.003), but was found only in babies who were not HIV infected. The combination A1, B8, DR3, in contrast, was found less often than expected in our study group (RR = 0.39) and was disproportionately represented amongst the infected babies. We have observed an unexpectedly low (6 per cent) mother-to-infant transmission rate of HIV among prospectively studied intravenous drug users. We speculate that the unusually high ratio of the common antigen combinations (often halotypes), A3, B7, DR2 to A1, B8, DR3 in this population may be contributory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742942

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  7 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  Mechanisms of resistance to HIV infection.

Authors:  W A Paxton; R A Koup
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission.

Authors:  Carey Farquhar; Sarah Rowland-Jones; Dorothy Mbori-Ngacha; Mary Redman; Barbara Lohman; Jennifer Slyker; Phelgona Otieno; Elizabeth Obimbo; Timothy Rostron; James Ochieng; Julius Oyugi; Rose Bosire; Grace John-Stewart
Journal:  AIDS Res Hum Retroviruses       Date:  2004-07       Impact factor: 2.205

4.  Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition.

Authors:  Sascha R Ellington; Caroline C King; Athena P Kourtis
Journal:  Future Virol       Date:  2011-11-24       Impact factor: 1.831

5.  Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method.

Authors:  R Winchester; Y Chen; S Rose; J Selby; W Borkowsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.

Authors:  Eva Ramírez de Arellano; Francisco Díez-Fuertes; Francisco Aguilar; Humberto Erick de la Torre Tarazona; Susana Sánchez-Lara; Yolanda Lao; José Luis Vicario; Felipe García; Juan González-Garcia; Federico Pulido; Félix Gutierrez-Rodero; Santiago Moreno; Jose Antonio Iribarren; Pompeyo Viciana; Carlos Vilches; Manuel Ramos; Laura Capa; José Alcamí; Margarita Del Val
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

Review 7.  Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.

Authors:  Omayma Amin; Jenna Powers; Katherine M Bricker; Ann Chahroudi
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.